MediWound (NASDAQ:MDWD) PT Set at $31.00 by HC Wainwright

MediWound (NASDAQ:MDWD) has been given a $31.00 price target by investment analysts at HC Wainwright in a report issued on Thursday, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 52.18% from the stock’s previous close.

Several other brokerages also recently commented on MDWD. Alliance Global Partners initiated coverage on shares of MediWound in a research note on Friday, May 2nd. They issued a “buy” rating and a $25.00 target price for the company. Wall Street Zen upgraded shares of MediWound to a “sell” rating in a research report on Friday, March 21st. Finally, Craig Hallum started coverage on MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.25.

MediWound Trading Up 0.1%

NASDAQ MDWD opened at $20.37 on Thursday. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00. The stock has a 50-day simple moving average of $17.46 and a 200 day simple moving average of $17.62. The company has a market capitalization of $220.16 million, a PE ratio of -7.02 and a beta of 0.30.

MediWound (NASDAQ:MDWD) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.58. The company had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company earned ($1.05) EPS. As a group, sell-side analysts predict that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MDWD. GAMMA Investing LLC increased its position in shares of MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,703 shares in the last quarter. R Squared Ltd acquired a new position in MediWound in the 4th quarter worth $32,000. Russell Investments Group Ltd. increased its holdings in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares in the last quarter. Corebridge Financial Inc. raised its stake in shares of MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 665 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the period. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.